Andrx Group
Article Abstract:
The Andrx Group's lack of a new drug, delayed drug launches, litigations and inventory writedowns weakened results in 2002 but its partnership with KudCo will help lift share price for some recovery in 2003. Shares have wide appreciation -potential for the next 3 - 5 years.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
King Pharmaceuticals Inc
Article Abstract:
King Pharmaceuticals Inc. will no longer be acquiring Elan's primary care business unit as a suit has arisen between the two and also because the SEC is inquiring into King's pricing practices. Although stock is timely, investors are advised to wait this one out.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Sigma-Aldrich
Article Abstract:
Sales of Sigma-Aldrich Corp.'s biochemical, organic chemical and chromatography products are stagnating with research and development expenses rising. Its net revenue may go into buying back stock, so its shares are unlikely to grow at market rate.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: